secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001213900-25-052635
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt appoints Evofem CEO Saundra Pelletier to board; officer loans $70K
-------------------------------------------------------------------------

- Board appoints Saundra Pelletier (CEO of Evofem) as director, effective June 5, 2025.
- Chief Innovation Officer Shahrokh Shabahang loans $70,000 at 7.5%, due Dec 5, 2025.
- Weekly update: Adimune targets Q4 2025 regulatory submission for ADI-100 autoimmune therapy.
- Evofem generated $20M net revenue in 2024; CEO cites capital dependency for growth.
- Pending Evofem merger extended to Sept 30, 2025; capital needed for milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025052635/0001213900-25-052635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025052635/ea0245171-8k_aditxt.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-052635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer